Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Leukemia & Lymphoma|September 21, 2018
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenanceNatali Pflug, Paula Cramer, Sandra Robrecht, et al.
Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Oncoimmunology|July 30, 2016
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiotaNatali Pflug, Sandra Kluth, Jörg J Vehreschild, et al.
Haematologica|August 29, 2015
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)Paula Cramer, Susanne Isfort, Jasmin Bahlo, et al.
Leukemia|April 15, 2025
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemiaAnnika Dechow, Sanna Timonen, Aleksandr Ianevski, et al.
Blood|May 7, 2014
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemiaNatali Pflug, Jasmin Bahlo, Tait D Shanafelt, et al.
Nature Medicine|February 21, 2025
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibodyTill Braun, Michael Rade, Maximilian Merz, et al.
European Journal of Haematology|December 9, 2015
Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemiaChristian Maurer, Natali Pflug, Jasmin Bahlo, et al.
Haematologica|February 29, 2020
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trialPaula Cramer, Julia V Tresckow, Sandra Robrecht, et al.
Nature Communications|March 10, 2026
Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progressionLinus Wahnschaffe, Dennis Jungherz, Tony A Müller, et al.
Pageof 2